GLP-2 (TRZ) / Ipamorelin

Structural studies have examined how the GLP-2 (TRZ) component engages incretin receptors. Cryo-EM analyses by Zhao and colleagues (2022, Nature Communications) determined structures of this acylated peptide bound to both GIPR and GLP-1R, showing that the first 30–39 residues adopt an α-helical conformation analogous to native GIP. The peptide carries Aib residues at positions 2 and 13 and a C-terminal amide; the C20 fatty-diacid at Lys^20 projects out of the binding pocket and confers albumin binding, underpinning the peptide's extended circulating lifetime. That work characterized how key polar contacts at the GIPR binding interface are arranged and how the acylated side chain is accommodated in each receptor complex. The findings situated GLP-2 (TRZ) within the class B GPCR pharmacology framework and provided the molecular basis for its dual-receptor engagement.

Biochemical and cell-based assays have characterized the GLP-2 (TRZ) peptide's signaling at incretin receptors. It activates Gs-coupled cAMP signaling at the GIP receptor and also engages the GLP-1 receptor, with assays examining its relative receptor-activation profile at each target. In vitro experiments in pancreatic β-cell lines and rodent islet preparations have been used to assess insulinotropic signaling, comparing the dual-receptor agonist to mono-agonist controls. Mutagenesis of receptor extracellular-loop residues has probed the structural contributions of the modified Lys^20 tail to GIPR binding, providing mechanistic detail on how the lipidated modification affects receptor contact geometry. The pharmacology review by Galindo and colleagues (2026, Diabetes Therapy) provided a narrative synthesis of dual GIP/GLP-1 receptor agonist pharmacology.

Ipamorelin's pharmacology has been examined as a selective GH secretagogue. The foundational characterization by Raun and colleagues (1998, European Journal of Endocrinology) used in vitro rat pituitary cell assays and an in vivo conscious-swine model to characterize GH release and assess selectivity at other pituitary hormone axes, including ACTH and cortisol, establishing GHS-R1a (the ghrelin receptor) as the primary target. Receptor-binding and mutagenesis studies have identified the structural features underlying GHS-R1a engagement: residues including the N-terminal Aib and D-2Nal occupy hydrophobic receptor pockets, with the Lys-NH2 terminus making polar contacts. Liu and colleagues (2021, Nature Communications) reported cryo-EM structures of the human ghrelin receptor in complex with ghrelin and a small-molecule agonist, providing a structural framework for modeling class A GPCR agonism relevant to peptide secretagogue research. The review by Shiimura and colleagues (2025, Frontiers in Molecular Neuroscience) synthesized ghrelin receptor ligand-recognition research in broader context.

No peer-reviewed primary study or registered clinical trial in the available literature has directly examined the GLP-2 (TRZ) plus Ipamorelin combination. The rationale for a combined preparation in research settings rests on the two components acting through distinct, non-overlapping GPCR systems: incretin-receptor Gs/cAMP signaling on one hand and GHS-R1a calcium/Gq signaling on the other. In published preclinical work, each peptide has been studied separately as a pharmacological tool — the GIP analog in incretin-receptor and structural models and ipamorelin in GH-secretion and receptor-pharmacology models — without direct evidence of interaction being reported for this specific pairing. Any experimental use of the blend would represent an extrapolation from single-component literature rather than a characterized combination.